Vinay Prasad, MD MPH

Plenary Session

Science EN ↓ 399 episodes

A podcast on medicine, oncology, & health policy. Host: Vinay Prasad, MD MPH from University of California, San Francisco. Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com.

Author

Vinay Prasad, MD MPH

Category

Science

Podcast website

soundcloud.com

Latest episode

May 20, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 5M+ downloads · 4.8 rating iOS soon

Episodes

1.48 Falsified Data in Meta-Analyses and the Expert Halo Effect with Dr. Stephanie Halvorson 13.03.2019

This week we dive deep into an article in JAMA IM on falsified data in meta-analyses. We also discuss the recent JAMA viewpoint "Reducing the Expert Halo Effect on Pharmacy and Therapeutics Committees" with its author, Dr. Stephanie Halvorson of OHSU. Falsified data: doi.org/10.1001/jamainternmed.2014.7774 Expert Halo Effect: doi.org/10.1001/jama.2018.20789 Back us on Patreon! www.patreon.com/plen...

1.47 BONUS! Medical Reversal: Class Lecture 11.03.2019

This BONUS episode is a lecture on medical reversal that was pre-recorded for a class at Harvard Medical School. The recording was played for students in February of 2019 and followed by a Q&A. The slides referenced are available to Patreon supporters. Back us on Patreon! www.patreon.com/plenarysession

1.46 BONUS! Personal Finances with Dr. Tom Beer 08.03.2019

In this bonus episode, we bring back Dr. Tom Beer of OHSU from episode 1.33 to discuss how to manage your personal finances. The interview is aimed at young physicians, but there is something for all audiences as we cover a broad range of topics: paying off loans, optimizing retirement savings, buying a home, and investing. Back us on Patreon! www.patreon.com/plenarysession

1.45 Real-World Data, Gottlieb, & Using the EHR for Meaningful Improvement with Dr. Deborah Cohen 06.03.2019

This week's episode begins with praise for the recent article by Booth CM, Karim S, and Mackillop WJ on real-world data published in Nature Reviews Clinical Oncology. Next, we tackle the resignation of Scott Gottlieb as FDA commissioner and how we can measure the success of the FDA. Finally, we have an interview with Dr. Deborah Cohen of OHSU on effective communication between the clinician and th...

1.44 BONUS! Screen Time and Children's Performance 01.03.2019

This BONUS episode is the recording of a lecture given as part of the medical school class Appraising Medical Literature, taught at OHSU. This clip from the class critiques the recent JAMA Pediatrics paper "Association Between Screen Time and Children’s Performance on a Developmental Screening Test". Screen Time: doi.org/10.1001/jamapediatrics.2018.5056 Back us on Patreon! www.patreon.com/plenarys...

1.43 Andexanet Alfa with Dr. Tom Deloughery & National Medicaid Policy with Dr. John McConnell 22.02.2019

In this episode we discuss the controversy over the recent article in NEJM, "Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors", with Dr. Tom Deloughery of OHSU. We end with an interview with Dr. John McConnell, also of OHSU, on health economics and Medicaid. Andexanet Alfa: doi.org/10.1056/NEJMoa1814051 Back us on Patreon! www.patreon.com/plenarysession

1.42 Caplacizumab for TTP with Dr. Sven Olson & Economics of Drug Pricing with Dr. Inma Hernández 13.02.2019

In the first half of this episode, Dr. Sven Olson of OHSU joins us to help critique the recent NEJM paper, "Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura". In the second half, we interview Dr. Inmaculada Hernández of the University of Pittsburgh on her work on the economic principles behind runaway drug prices. Caplacizumab: doi.org/10.1056/NEJMoa1806311 Back us on Patreo...

1.41 Geneva Oath and Financial Relationships Among Guideline Authors with Dr. Joshua Niforatos 09.02.2019

We feature two interviews this week: the first is a hallway conversation with [soon-to-be] Dr. Antonious Hazim of OHSU on the Declaration of Geneva and the second is a discussion with [soon-to-be] Dr. Joshua Niforatos on his recent paper in The American Journal of Emergency Medicine, titled "Financial relationships with industry among guideline authors for the management of acute ischemic stroke"....

1.40 The World of Hematology with Dr. Thomas Deloughery 06.02.2019

This episode features an interview with hematologist Dr. Thomas Deloughery of OHSU. We cover a broad range of topics including 23andMe, wilderness medicine, academia, and Twitter. We'll be back next week with our regular introductory monologue! Back us on Patreon! www.patreon.com/plenarysession

1.39 Looking Back On a Tenure in Medicine with Dr. Alex Denes 02.02.2019

In this episode we interview Dr. Alex Denes of OHSU on his decades-long career in medicine: what practices have changed and what have stayed the same. No monologue this week - we'll be back next week with more insights! Back us on Patreon! www.patreon.com/plenarysession

1.38 Lartruvo, New Directions for Cancer Trials, Gene Expression Profiling, & Dr. Miriam Knoll 26.01.2019

In this episode we tackle Eli Lilly's drug Lartruvo (olaratumab) and the under-powered phase II trial that led to its FDA accelerated approval; a viewpoint in JAMA on new directions for cancer trials; and gene expression profiling for carcinoma of unknown primary. We end with an interview with Dr. Miriam Knoll of Hackensack Meridian Health on employment after residency or fellowship, residency tra...

1.37 BONUS! Medical Reversal for a General Audience 18.01.2019

This BONUS episode is the recording of a talk given at the Salem City Club on January 11, 2019. It's the talk on medical reversal that has been featured in previous episodes, but this time the format and content have been updated for a broader, more general audience. Back us on Patreon! www.patreon.com/plenarysession

1.36 Generic Price Competition & Military Surgical Advances with Dr. Martin Schreiber 15.01.2019

This week we dive into the recent paper by Drs. Cole and Dusetzina titled "Generic Price Competition For Specialty Drugs: Too Little, Too Late?". We also have an interview with Dr. Martin Schreiber of OHSU on his experiences as a trauma surgeon, both stateside and on the battlefield. Generic Price Competition: https://doi.org/10.1377/hlthaff.2017.1684 Back us on Patreon! www.patreon.com/plenaryses...

1.35 BONUS! Conflict of Interest in Oncology 10.01.2019

This BONUS episode is the recording of a lecture given to the Bioethics Study Group at OHSU on January 9, 2019 on conflict of interest, specifically in the field of oncology. Backers of our Patreon will be sent accompanying slides. Back us on Patreon! www.patreon.com/plenarysession

1.34 Endpoints in ECOG-ACRIN 2511, Update to KEYNOTE-024, & Mentorship with Dr. Joseph Shatzel 10.01.2019

In this episode, we discuss two recent papers published in the Journal of Clinical Oncology: ECOG-ACRIN 2511 and the update adding overall-survival and crossover results to KEYNOTE-024. We end with an interview with Dr. Joseph Shatzel of OHSU on mentorship. ECOG-ACRIN 2511: http://doi.org/10.1200/JCO.18.00264 KEYNOTE-024 update: http://doi.org/10.1200/JCO.18.00149 Back us on Patreon! www.patreon.c...

1.33 Guarantee-Time Bias & Trials, Philanthropy, and Cancer Research with Dr. Tom Beer 05.01.2019

In this episode we discuss guarantee-time bias in the context of the recent JAMA Oncology paper titled "Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer". We also have an interview with Dr. Tom Beer, the Deputy Director of the OHSU Knight Cancer Institute, on clinical trials, leadership, philanthropy, and future directions in cance...

1.32.1 Radiation Oncology with Dr. Brian Kavanagh 04.01.2019

Episode 1.32 ran a little long, so this is episode 1.32.1 - we broke out the interview with Dr. Brian Kavanagh, the Chairman of Radiation Oncology at the University of Colorado, to make the interview more accessible. Back us on Patreon! www.patreon.com/plenarysession

1.32 Rating Metrics, Conflict of Interest in the News, & Radiation Oncology with Dr. Brian Kavanagh 03.01.2019

This week we discuss various academic indices including the h-index and the new Altmetric score, and we go over the recent NY Times article on conflict of interest. We end with an interview with Dr. Brian Kavanagh, the Chairman of Radiation Oncology at the University of Colorado. NY Times: https://www.nytimes.com/2018/12/31/upshot/congratulations-on-the-promotion-but-did-science-get-a-demotion.htm...

1.31 Ketogenic Diet, COMET-1 and COMET-2, the Health Insurance Marketplace with Dr. Jane Zhu 27.12.2018

We begin this episode with a discussion of Dr. Mukherjee's ongoing study combining a ketogenic diet with PI3 kinase inhibition. We continue with a take on a recent reanalysis of COMET-1 and COMET-2, two failed randomized controlled trials of cabozantinib versus prednisone or mitoxantrone-prednisone in metastatic castration-resistant prostate cancer. We end with an interview on instabilities in the...

1.30 BONUS! Clinical Trial Endpoints, Drug Approval, Incentives in Oncology 19.12.2018

This BONUS episode is the recording of a lecture given to the National Breast Cancer Coalition on December 11, 2018. It's on clinical trial endpoints, FDA drug approval, and incentives in oncology. Backers of our Patreon will be sent accompanying slides. Back us on Patreon! www.patreon.com/plenarysession

1.29 RCT of Parachutes and Frameworks for Internal Medicine with Dr. Andre Mansoor 18.12.2018

We begin this episode with a critique of the recent paper in the BMJ, "Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial" and we end it with an interview with Dr. Andre Mansoor, discussing his new book: "Frameworks for Internal Medicine." Parachutes: https://www.bmj.com/content/363/bmj.k5094 Back us on Patreon! https://www.patreon.com/plenaryse...

1.28 Questionable FDA Drug Approvals and Building a Career with Dr. Chadi Nabhan 13.12.2018

In this episode we critique two recent FDA drug approvals (venetoclax in combination with azacitidine or decitabine or low-dose cytarabine; glasdegib in combination with low-dose cytarabine -- both for acute myeloid leukemia)and we interview Dr. Chadi Nabhan, the Chief Medical Officer of Cardinal Health, on career transitions. The interview was taped on location at the 2018 annual conference of th...

1.27 BONUS! Medical Reversal 06.12.2018

This BONUS episode is the recording of a lecture given to hospitalists at Kaiser Permanente on November 14, 2018. It's a slightly different version of the talk on medical reversals that we recorded for episode 1.16. Backers of our Patreon will be sent accompanying slides. Back us on Patreon: https://www.patreon.com/plenarysession

1.26 Lesson From an ASH Abstract, Behind the Scenes of a Residency Program with Dr. Sima Desai 04.12.2018

Having just returned from the 2018 American Society of Hematology (ASH) Annual Meeting, we begin this episode by discussing the abstract of a study that stretches its conclusions. We dedicate most of the episode to an interview with Dr. Sima Desai, the program director for OHSU's Internal Medicine Residency Program. She gives some great insight on the program's inner workings. ASH abstract: https:...

1.25 Welch's Legacy, Interpreting NGS, Uncertainty over Pregabalin, Beyond EBM with Dr. Sam Edwards 27.11.2018

In this episode we discuss: Dr. Gilbert Welch's Wikipedia page and how we should keep his decades of work in perspective, a Twitter conversation between experts on differing interpretations of results from next-generation sequencing, the new paper in JAMA titled "Assessment of Pregabalin Postapproval Trials and the Suggestion of Efficacy for New Indications", and finally, along with Dr. Sam Edward...

Listen to the Plenary Session podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.